ONSD as an ICP Marker in vNOTES and TLH

Effect of Surgical Approach on Optic Nerve Sheath Diameter as a Surrogate Marker of Intracranial Pressure: A Comparison Between vNOTES and Total Laparoscopic Hysterectomy

Patients undergoing conventional total laparoscopic hysterectomy (TLH) are typically placed in the Trendelenburg position with intraabdominal carbon dioxide (CO₂) insufflation. These factors may contribute to intraoperative complications such as lymphedema, impaired pulmonary function, and increased intracranial pressure.

Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES), a novel minimally invasive technique, provides retroperitoneal or transperitoneal access through the vaginal route and offers the potential for shorter operative times and lower intraabdominal pressure requirements.

This study aims to evaluate whether the vNOTES technique can reduce intraoperative and postoperative complications compared with TLH. Particular attention will be given to hemodynamic parameters and changes in optic nerve sheath diameter as an indirect indicator of intracranial pressure.

Study Overview

Detailed Description

This study is designed as a single-center, prospective, randomized controlled trial conducted at the Gynecologic Oncology Clinic of Health Sciences University Diyarbakır Gazi Yaşargil Training and Research Hospital. Eligible patients will be women between 18 and 75 years of age, classified as ASA I-II, who are scheduled for elective laparoscopic hysterectomy for gynecologic oncology indications. The study protocol will be initiated after approval by the institutional ethics committee, and written informed consent will be obtained from all participants.

Group vNOTES: Following vaginal exposure with a speculum under general anesthesia, entry will be performed through the posterior vaginal fornix. After posterior colpotomy, the vNOTES port system will be inserted. Pneumoperitoneum will be established with CO₂ insufflation at a maximum pressure of 15 mmHg. The operation will be performed using an endoscopic camera and working channels.

Group TLH: Under general anesthesia, pneumoperitoneum will be created via an umbilical trocar (maximum pressure15 mmHg), followed by placement of 2-3 additional trocars in the lower abdomen. A standard total laparoscopic hysterectomy will then be performed.

Demographic and perioperative data will be collected, including age, diagnosis, ASA score, anesthesia and surgery duration, intraoperative blood loss (by suction and sponge count), total intravenous fluids, systolic and diastolic blood pressure, heart rate, oxygen saturation, respiratory rate, end-tidal CO₂, intra-abdominal pressure, and ventilatory parameters (PEEP, peak and plateau airway pressures).

The primary outcome will be changes in optic nerve sheath diameter (ONSD), measured by ultrasonography at predefined time points as a surrogate marker of intracranial pressure:

T0: before induction of anesthesia

T1: at 10 minutes after Trendelenburg positioning and insufflation

T2: at 30 minutes

T3: at 60 minutes

T4: at 90 minutes

T5: 10 minutes after desufflation and return to neutral position

All ONSD measurements will be performed intraoperatively by a trained anesthesiologist using standardized ultrasound techniques. Hemodynamic and ventilatory parameters will be recorded at 10-minute intervals.

Secondary outcomes will include arterial blood gas analysis, postoperative complications (such as nausea, vomiting, delirium, headache, dizziness, and diplopia), and recovery variables (time to ambulation, return of bowel function, oral intake, and hospital stay).

Among the parameters measured, ONSD evaluation via ultrasound is specific to the study and non-invasive, adding no risk or cost to the patient. All other parameters are part of routine intraoperative monitoring. Data collection will be carried out in the operating room by anesthesiologists and trained ICU/gynecologic oncology nurses.

The investigators hypothesize that the vNOTES approach, due to its shorter operative duration, reduced Trendelenburg requirements, and lower intraabdominal insufflation pressures, will result in less pronounced increases in ONSD compared with TLH. This may lead to greater intraoperative stability and reduced postoperative complications, thereby providing valuable evidence for optimizing surgical strategies in gynecologic oncology.

Study Type

Interventional

Enrollment (Actual)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Outside of the US
      • Diyarbakır, Outside of the US, Turkey (Türkiye), 21070
        • Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • voluntary participation,
  • elective laparoscopic hysterectomy scheduled by gynecology-oncology specialists,
  • ASA physical status I-II

Exclusion Criteria:

  • included unwillingness to participate,
  • emergency surgery,
  • age <18 years,
  • prior major pelvic or abdominal surgery,
  • ASA ≥III,
  • Chronic pulmonary disease, pulmonary hypertension, glaucoma, diabetic retinopathy, intracranial pathology (mass, hydrocephalus, optic neuritis), prior ocular or intracranial surgery, cardiac failure (EF <40%), active infection, or systemic inflammatory diseases other than malignancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: vNOTES Hysterectomy for Assessment of Intraoperative Optic Nerve Sheath Diameter
Vajinal natural orifice transluminal endoscopic surgery (vNOTES): In the vNOTES group, the surgery was performed using a transvaginal approach with a self-retaining vaginal port. Following colpotomy, CO₂ insufflation was applied through the vaginal port, ensuring intra-abdominal pressure did not exceed 15 mmHg. The procedure involved occlusion and ligation of the uterine artery under direct endoscopic visualization, followed by sampling through the vaginal route. Pneumoperitoneum was released before closing the vaginal vault. The uterus was then removed through the vaginal route.
vNOTES: In the vNOTES group, the surgery was performed using a transvaginal approach with a self-retaining vaginal port. Following colpotomy, CO₂ insufflation was applied through the vaginal port, ensuring intra-abdominal pressure did not exceed 15 mmHg. The procedure involved occlusion and ligation of the uterine artery under direct endoscopic visualization, followed by sampling through the vaginal route. Pneumoperitoneum was released before closing the vaginal vault. The uterus was then removed through the vaginal route.
Active Comparator: Total Laparoscopic Hysterectomy for Assessment of Intraoperative Optic Nerve Sheath Diameter
Total laparoscopic hysterectomy (TLH): In the TLH group, the surgical procedure was performed under standard laparoscopic conditions using a 10 mm umbilical camera port and two 5 mm accessory trocars. CO₂ insufflation was initiated to maintain intra-abdominal pressure below 15 mmHg. The uterus is dissected using a bipolar vessel sealing device, and the specimen is removed transvaginally. The vaginal cuff and abdominal trocar entries are sutured laparoscopically under direct visualization.
In the TLH group, the surgical procedure was performed under standard laparoscopic conditions using a 10 mm umbilical camera port and two 5 mm accessory trocars. CO₂ insufflation was initiated to maintain intra-abdominal pressure below 15 mmHg. The uterus is dissected using a bipolar vessel sealing device, and the specimen is removed transvaginally. The vaginal cuff and abdominal trocar entries are sutured laparoscopically under direct visualization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Optic nerve sheath diameter (ONSD) measured
Time Frame: From baseline (before induction) to 10, 30, 60, and 90 minutes after Trendelenburg and CO₂ insufflation, and 10 minutes after desufflation.
All measurements were performed using a high-resolution ultrasound device equipped with a 7-13 MHz linear probe. The ultrasound gain and depth settings were standardized for all patients (depth: 4-5 cm; focus: at the level of the optic disc). Patient Position: Measurements were obtained with patients in the supine position. The eyes were kept closed, and sterile ultrasound gel was applied without exerting pressure on the globe. The probe was gently placed on the upper eyelid, and measurements were taken in the transverse plane. The optic nerve sheath diameter was measured 3 mm distal to the optic disc, from outer edge to outer edge (outer-to-outer).
From baseline (before induction) to 10, 30, 60, and 90 minutes after Trendelenburg and CO₂ insufflation, and 10 minutes after desufflation.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure measurement
Time Frame: It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
Systolic, diastolic and mean arterial pressure measurements will be recorded by invasive arterial monitoring.
It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
Measurement of heart rate
Time Frame: It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
The number of heart beats per minute obtained by electrocardiographic monitoring
It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
Nausea-vomiting
Time Frame: During the 24 hours postoperative period
Questioning about the presence/absence of nausea and/or vomiting in the postoperative period
During the 24 hours postoperative period
intraabdominal pressure
Time Frame: It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
The pressure inside the abdominal cavity during CO₂ insufflation.
It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
end-tidal CO₂ (EtCO₂)
Time Frame: It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
The partial pressure of CO₂ at end-expiration measured by capnography
It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
peak airway pressure
Time Frame: It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
The highest pressure reached in the airways during inspiration under mechanical ventilation.
It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.
dizziness
Time Frame: During the 24 hours postoperative period
Questioning about the presence/absence of dizzines the postoperative period
During the 24 hours postoperative period
diplopia
Time Frame: During the 24 hours postoperative period
Questioning about the presence/absence of diplopia the postoperative period
During the 24 hours postoperative period
Incidence of Postoperative Headache
Time Frame: Within the first 24 hours postoperatively
The incidence of postoperative headache will be recorded within the first 24 hours after surgery. Headache will be assessed by direct patient questioning and documented as present or absent.
Within the first 24 hours postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Fatma Acil, M.D., Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 27, 2025

Primary Completion (Actual)

January 2, 2026

Study Completion (Actual)

January 5, 2026

Study Registration Dates

First Submitted

November 18, 2025

First Submitted That Met QC Criteria

November 18, 2025

First Posted (Estimated)

November 26, 2025

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

January 5, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data (IPD), including baseline demographic variables and primary/secondary outcome measures, will be shared.

IPD Sharing Time Frame

study completion + 6 months

IPD Sharing Access Criteria

Researchers may request access to the de-identified IPD by contacting the principal investigator at:[acilfatma@gmail.com].

Requests will be evaluated by the investigators, and data will be shared after approval and completion of a data-sharing agreement."

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endometrial Cancer

Clinical Trials on vNOTES

Subscribe